Viibryd Approved for Major Depressive Disorder

When symptoms of depression interfere with daily life

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Jan. 24, 2011 (HealthDay News) -- Viibryd (vilazodone hydrochloride) tablets have been approved by the U.S. Food and Drug Administration to treat symptoms of major depressive disorder (MDD) in adults.

MDD is diagnosed when daily life is affected by symptoms that may include depressed mood, loss of interest in once-pleasurable activities, significant changes in weight or appetite, and changes in sleep habits. Episodes can occur only once or multiple times throughout a person's lifetime, the FDA said in a news release.

In clinical testing, adverse reactions to Viibryd included diarrhea, nausea, vomiting and insomnia.

Viibryd and all other approved antidepressants have a boxed label warning that they have shown an increased risk of suicidal thinking among children, teens, and young adults aged 18 to 24, the FDA said.

Viibryd is manufactured by PGXHealth, based in New Haven, Conn.

More information

The U.S. National Institute of Mental Health has more about depression.


Last Updated: